Bank Julius Baer & Co’s Quest Diagnostics DGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
– Sell
-393
Closed -$70.6K – 680
2025
Q2
$70.6K Hold
393
– – ﹤0.01% 525
2025
Q1
$66.5K Sell
393
-34
-8% -$5.58K ﹤0.01% 521
2024
Q4
$71.1K Buy
427
+30
+8% +$4.67K ﹤0.01% 511
2024
Q3
$73.1K Buy
+397
New +$59.3K ﹤0.01% 447
2023
Q2
– Sell
-1,803
Closed -$255K – 567
2023
Q1
$255K Buy
1,803
+831
+85% +$119K ﹤0.01% 414
2022
Q4
$152K Buy
972
+2
+0.2% +$287 ﹤0.01% 447
2022
Q3
$119K Sell
970
-344
-26% -$45.3K ﹤0.01% 445
2022
Q2
$175K Buy
1,314
+19
+1% +$2.59K ﹤0.01% 420
2022
Q1
$177K Buy
1,295
+24
+2% +$3.35K ﹤0.01% 426
2021
Q4
$220K Buy
1,271
+54
+4% +$8.22K ﹤0.01% 523
2021
Q3
$177K Sell
1,217
-1,511
-55% -$221K ﹤0.01% 554
2021
Q2
$360K Sell
2,728
-263
-9% -$34.4K ﹤0.01% 492
2021
Q1
$384K Buy
2,991
+885
+42% +$109K ﹤0.01% 486
2020
Q4
$251K Buy
2,106
+1,833
+671% +$223K ﹤0.01% 535
2020
Q3
$31K Buy
+273
New +$32.3K ﹤0.01% 639
2020
Q2
– Sell
-1,737
Closed -$139K – 697
2020
Q1
$139K Buy
+1,737
New +$180K ﹤0.01% 451

Other funds holding DGX

Bank Julius Baer & Co's DGX Position: Q3 2025 in Review

Bank Julius Baer & Co sold out of Quest Diagnostics (DGX) in Q3 2025, closing a stake of 393 shares — an estimated $70.6K sold.

Bank Julius Baer & Co first reported a position in DGX in Q1 2020 and held it in 16 quarters. The position peaked at $384K in Q1 2021. 1,006 funds tracked by Wall St. Rank hold DGX as of Q3 2025.

  • Bank Julius Baer & Co reported no remaining Quest Diagnostics position as of Q3 2025 after selling out during the quarter.
  • Bank Julius Baer & Co sold 393 Quest Diagnostics shares in Q3 2025, an estimated $70.6K.
  • Bank Julius Baer & Co first reported a position in Quest Diagnostics in Q1 2020 and held it in 16 quarters.
  • Bank Julius Baer & Co's Quest Diagnostics position peaked at $384K in Q1 2021.
  • 1,006 funds tracked by Wall St. Rank held Quest Diagnostics as of Q3 2025.

Based on Bank Julius Baer & Co's 13F filing for Q3 2025, filed 13 Nov 2025.